Oryzon Genomics is a clinical stage biopharmaceutical company developing innovative therapies in the field of epigenetics.
A scientifically and clinically validated epigenetic platform with two therapeutic programs in clinical development having multiple indication opportunities.
Ozyzon Genomics has signed a global strategic partnership with ROCHE valued at $500M for its lead program.
ORY-1001, a LSD1 program in clinical trials for leukemia and small cell lung cancer.
ORY 2001, an unencumbered LSD1-MAOB program, is set to enter phase IIA in Alzheimer’s Disease, Multiple Sclerosis and Huntington’s Disease.
Oryzon Genomics needed to strengthen its cash position ahead of planned developments in neurodegenerative diseases and more generally to fund its R&D activities.
Additionally the company wanted to expand its international shareholder base .
Bryan, Garnier & Co acted as joint book runner alongside Guggenheim Securities, LLC.
The shares were sold at a price of EUR 3.20 per share corresponding to a 17.9% discount to last price.
The capital increase was oversubscribed and raised gross proceeds of approximately EUR 18.2 million.
The offering was marketed to institutional investors specialized in healthcare and life sciences from the US, Spain and the rest of Europe.
The majority of the funds were raised from international investors, reinforcing and diversifying the company’s shareholder base.
Founded in 2000 in Barcelona, Spain, Oryzon is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with Roche. Oryzon’s LSD1 program is currently covered by + 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts.
About Bryan, Garnier & Co
Bryan, Garnier & Co is a European, full service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Media & Telecoms, Healthcare, Smart Industries & Energy, Consumer, Brands & Retail and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich and New York. The firm is a member of the London Stock Exchange and Euronext.
Co-Founder & Managing Partner
T: +33 1 56 68 75 29
T: +33 1 70 36 57 22
Managing Director, ECM
T: +1 56 68 75 17
Brigitte de Lima
T: +44 207 332 2545
T: +33 1 56 68 75 30